VIRAMUNE Drug Patent Profile

« Back to Dashboard

When do Viramune patents expire, and when can generic versions of Viramune launch?

Viramune is a drug marketed by Boehringer Ingelheim and is included in three NDAs. There is one patent protecting this drug.

The generic ingredient in VIRAMUNE is nevirapine. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the nevirapine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viramune

A generic version of VIRAMUNE was approved as nevirapine by AUROBINDO on May 22^nd, 2012.

Summary for VIRAMUNE

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	121
Clinical Trials:	42
Patent Applications:	4,729
Drug Prices:	Drug price information for VIRAMUNE
What excipients (inactive ingredients) are in VIRAMUNE?	VIRAMUNE excipients list
DailyMed Link:	VIRAMUNE at DailyMed

See drug prices for VIRAMUNE

Recent Clinical Trials for VIRAMUNE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Witwatersrand, South Africa	Phase 4
National Institutes of Health (NIH)	Phase 4
Columbia University	Phase 4

See all VIRAMUNE clinical trials

US Patents and Regulatory Information for VIRAMUNE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	VIRAMUNE	nevirapine	SUSPENSION;ORAL	020933-001	Sep 11, 1998		DISCN	Yes	No
Boehringer Ingelheim	VIRAMUNE XR	nevirapine	TABLET, EXTENDED RELEASE;ORAL	201152-001	Mar 25, 2011		DISCN	Yes	No	8,460,704
Boehringer Ingelheim	VIRAMUNE	nevirapine	TABLET;ORAL	020636-001	Jun 21, 1996		DISCN	Yes	No
Boehringer Ingelheim	VIRAMUNE XR	nevirapine	TABLET, EXTENDED RELEASE;ORAL	201152-002	Nov 8, 2012		DISCN	Yes	No

EU/EMA Drug Approvals for VIRAMUNE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Viramune	nevirapine	EMEA/H/C/000183Tablets and oral suspensionViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents, and children of any age.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.50- and 100-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.400-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.	Authorised	no	no	no	1998-02-04
Teva B.V.	Nevirapine Teva	nevirapine	EMEA/H/C/001119Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV 1 infected adults, adolescents, and children of any age.Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.	Withdrawn	yes	no	no	2009-11-30

International Patents for VIRAMUNE

See the table below for patents covering VIRAMUNE around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	179	5 11-Dihydro-6H-Dipyrido (3, 2-b:2', 3'-e) (1,4) Diazepines and their use in the prevention and treatment of HIV infection.
African Regional IP Organization (ARIPO)	189	5,11 Dihydro-6H-dipyrido (3,2-b:2, 3 -e)(1,4)-diazepin-6-ones and thions and their use for the treatment of aids.
African Regional IP Organization (ARIPO)	9000188
African Regional IP Organization (ARIPO)	9000224
Austria	103918
Austria	177744
Austria	91128

Supplementary Protection Certificates for VIRAMUNE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0429987	990022	Netherlands		990022, 20101116, EXPIRES: 20121222
0429987	SPC/GB99/020	United Kingdom		PRODUCT NAME: NEVIRAPINE = 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B:2',3'-E)(1,4)DIAZEPIN-6-ONE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTERED: CH 54393 19971223; UK EU/1/97/055/001 19980205
0429987	C990022	Netherlands		PRODUCT NAME: NEVIRAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION: CH 54393 19971223
0429987	99C0019	France		PRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGUSTRATION: CH/LI 54 393 19971223
0429987	9990018-5 9991018-4	Sweden		PRODUCT NAME: 5,11-DIHYDRO-6H-DIPYRIDO3,2-B:2,3-E1,4DIAZEPINER OCH DERAS ANVAENDNING VID PREVENTION ELLER BEHANDLING AV HIV-INFEKTION; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRTION: LI 54393 19971223
0429987	99C0021	Belgium		PRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION NO/DATE: CH 54393 19971223
0429987	18/1999	Austria		PRODUCT NAME: NEVIRAPINE; REGISTRATION NO/DATE: EU/1/97/055/001 19980205

VIRAMUNE market dynamics and financial trajectory: revenue trends, exclusivity pressure, and competitive headwinds for (lamivudine) formulations

Last updated: July 19, 2026

VIRAMUNE (brand name for nevirapine, an NNRTI antiretroviral) is a legacy HIV therapy with declining brand economics in most markets as treatment standards shifted toward newer regimens and as manufacturer-specific formulations faced patent and exclusivity rollover. The current business picture is dominated by: (1) mature generic penetration in many jurisdictions, (2) constrained uptake driven by guideline preference for once-daily, lower-toxicity NNRTIs or integrase-based regimens, and (3) residual demand pockets where nevirapine remains in place due to regimen continuity, pregnancy management history, resistance profiles, or formulary inertia.

Below is the market and financial trajectory framework that typically governs VIRAMUNE’s revenue performance: competitive intensity, payer behavior, regulatory status, and patent-driven risk windows for generics and competing NNRTI brands.

---

What is VIRAMUNE (nevirapine) and how does it perform in the HIV market?

VIRAMUNE is nevirapine, used as an NNRTI in HIV-1 infection. In the modern standard of care, nevirapine is less favored than integrase inhibitors and newer NNRTIs (including agents with better tolerability or dosing convenience). This has shifted VIRAMUNE’s market role from early-line cornerstone therapy to narrower use cases.

Core demand drivers

• Switch-maintenance behavior: patients already controlled on NNRTI regimens can stay on therapy to avoid viral destabilization.
• Clinical scenarios where nevirapine has historical role in practice patterns.
• Availability and cost: where generics of nevirapine are embedded in formularies, brand economics depend on whether the brand retains any pricing leverage.

Core demand drags

• Guideline evolution away from older NNRTIs.
• Safety and monitoring intensity that can deter prescribers compared with newer NNRTIs.
• Generic substitution in countries where nevirapine is widely marketed.

---

How has VIRAMUNE revenue trended over time as generics expanded?

VIRAMUNE’s financial trajectory has followed the standard pattern for legacy HIV brands:

• Peak-era sales during HHV-era NNRTI adoption,
• Then sustained decline as:
  • generic nevirapine entered broadly,
  • treatment regimens shifted toward more potent, better-tolerated classes,
  • and payer formularies consolidated toward lower-cost preferred options.

Business model implication After generic entry, brand sales persist only where:

• branded supply remains preferred by institutions,
• contract pricing delays switching,
• or clinicians keep established patients on therapy.

In most mature markets, the long-run trajectory is a steep to moderate decline with episodic stabilization tied to payer negotiations, tender cycles, and legacy patient retention.

---

What market dynamics determine VIRAMUNE pricing and demand today?

1) Generic-to-brand substitution dynamics

Once multiple generic nevirapine products exist, brand pricing power collapses. Market share then tracks:

• tender awarded generic price floors,
• formulary restrictions on brand use,
• and pharmacy benefit design that favors generics.

2) Guideline alignment and regimen selection

Modern HIV treatment algorithms rely heavily on integrase inhibitors. NNRTIs still have roles, but nevirapine faces substitution from newer NNRTIs in many regions due to:

• dosing convenience,
• tolerability profiles,
• and fewer monitoring burdens in practice.

3) Supply chain and contracting cycles

Brand economics often become “contract-driven” rather than “standard-of-care driven.” Revenue resilience depends on:

• whether VIRAMUNE retains supply contracts at teaching hospitals and large systems,
• whether discontinuations or packaging changes cause switch events.

---

What patent and exclusivity events affect VIRAMUNE’s financial runway?

VIRAMUNE is a mature drug. The key commercial question is not “if,” but “how much” residual brand value remains after:

• patent expirations,
• formulation-related exclusivity (if any),
• and market saturation with generics.

Typical revenue-impact points

• Filing-to-grant uncertainty does not matter once generics are on market; the critical events are:
  • when key country-specific compositions and methods-of-use expire,
  • whether any product-specific supplements extend protection,
  • and whether litigation settlements delay generic launches.

What this means for brand revenue

• The financial trajectory turns sharply once the first meaningful generic wave hits.
• Subsequent declines are slower, driven by incremental share loss to low-cost competitors.

---

What generic entry risks exist for VIRAMUNE products?

Generic entry risk for nevirapine products is generally “high and structural” in mature geographies:

• the molecule is old and multiple generics exist,
• manufacturing is not typically blocked by complex biologics-style barriers,
• the regulatory path is usually abbreviated for small-molecule generics once reference is established.

Residual brand risk

• New solid oral dose variants, strengths, or packaging forms can prompt “late switch” even after initial generic penetration.
• Where brands keep contracts for longer cycles, switches cluster around renewal dates.

---

What is the Orange Book status of VIRAMUNE and how does it map to generic launch timing?

Orange Book status is the operational control point for:

• listed drug patents,
• whether patents are still active,
• and whether Paragraph IV certifications create launch delay via litigation.

For a full Orange Book mapping, the analysis must rely on the specific FDA label product(s) for nevirapine (including strength and dosage form). Without those specific product identifiers (listed drug name/strength/dosage form), the timeline-to-entry mapping cannot be produced accurately.

---

How does VIRAMUNE compare with competing NNRTIs on market share and payer preference?

In commercial terms, nevirapine competes with:

• newer NNRTIs with better convenience/tolerability,
• and integrase inhibitor-based preferred regimens that dominate first-line.

Competitive framework

• If a payer’s preferred formulary class is integrase inhibitor-based, VIRAMUNE demand shifts toward second-line or switch-through.
• If preferred NNRTIs exist, nevirapine competes on price and historical continuity rather than on clinical superiority.

Result for brand economics Brand share is usually limited and revenue is sensitive to:

• formulary updates,
• insurer prior authorization requirements,
• and pediatric or pregnancy program choices (where historical use can maintain baseline demand).

---

What formulations of nevirapine matter commercially for VIRAMUNE revenue?

Nevirapine is marketed in multiple dose forms historically:

• oral tablets in certain markets,
• oral solution in others.

Commercial impact:

• where oral solution formulations are supply-constrained or tendered separately, brand economics can persist longer in pediatrics or where liquid formulations are required.
• where tablets are dominant and generic tablet competition is extensive, brand decline accelerates.

---

Which companies dominate generic nevirapine and how does that shape pricing?

Generic market structure for mature small molecules usually becomes:

• a handful of dominant suppliers tied to distribution contracts and national tenders,
• plus additional entrants in secondary channels.

Pricing compression is driven by:

• procurement tender outcomes,
• vertical distribution agreements,
• and ongoing competitive entry.

For a quantified “who holds share” answer, product-level competitor identification and geography are required; absent that, the correct business conclusion remains structural: generic competition drives price floors.

---

What litigation or settlements have historically influenced nevirapine generic timing?

For legacy small molecules, litigation tends to matter mainly in:

• specific FDA Paragraph IV events,
• country-level patent disputes tied to particular formulations or processes.

Once multiple generics are established, litigation becomes less predictive of market-wide timing and more predictive of specific product launches. A complete litigation-to-timeline mapping requires case-level identification tied to the exact nevirapine brands and strengths.

---

What is the regulatory status of VIRAMUNE and how does it affect commercial prospects?

Regulatory constraints that influence commercial value include:

• label restrictions that affect prescriber comfort,
• safety monitoring requirements that can reduce adoption in real-world practice,
• manufacturing continuity and quality compliance that can affect supply availability.

For nevirapine, prescriber behavior is shaped by safety monitoring needs relative to newer regimens, which in turn limits brand-led growth. Commercially, this translates into “maintenance demand” rather than expansion.

---

How do revenue dynamics differ by geography for VIRAMUNE?

Geography drives outcomes through:

• generic penetration intensity,
• procurement and tender behavior,
• reimbursement design,
• and whether local clinical guidelines favor nevirapine in any structured program.

Typical pattern:

• In high-income markets: rapid generic substitution and low brand revenue contribution.
• In mid- to lower-income markets: brand availability and pricing policies vary widely; generic presence can still depress brand economics, but institutional procurement cycles can preserve some brand use longer than in high-income settings.

---

What is the likely financial trajectory if VIRAMUNE remains a legacy brand without new lifecycle extensions?

With no meaningful lifecycle extension that changes:

• dosing frequency,
• safety profile,
• or competitive advantage over preferred regimen classes,

the expected trajectory is:

• steady decline as remaining branded demand migrates to generics and newer standards,
• periodic short-term stabilization from institutional retention of existing patients and contracts,
• eventual “low single-digit market presence” economics in most mature markets where generics dominate.

---

Key data table: commercial trajectory drivers for VIRAMUNE

Variable	Near-term effect on VIRAMUNE revenue	Medium/long-term effect
Generic nevirapine penetration	Negative; compresses net price	Dominates long-run share
Guideline preference (integrase-based regimens)	Limits new initiations	Erodes remaining growth pockets
Institutional contracts/tenders	Can delay switching	Declines as contracts refresh
Safety/monitoring burden	Limits prescriber enthusiasm	Keeps adoption constrained
Formulation mix (tablet vs liquid)	Liquid shortages/tenders can preserve demand	Tablet generic saturation drives decline
Availability disruptions	Can temporarily lift constrained supply value	Not a sustainable revenue driver

---

Key Takeaways

• VIRAMUNE’s financial trajectory is constrained by structural competition from generic nevirapine and by modern HIV guideline preference for newer regimen classes.
• The brand’s revenue outlook is primarily “maintenance demand and contract-driven,” not “expansion-led.”
• Market share and net pricing are the dominant determinants; unless lifecycle extensions change competitive position, brand economics trend down as tenders and formularies refresh.
• Patent and exclusivity events matter mainly at specific geography and product-strength levels; once generic waves are established, litigation becomes less predictive for overall revenue.

---

FAQs

1) What typically happens to brand nevirapine sales after first generic entry?

Brand sales usually decline sharply due to payer and pharmacy substitution, followed by slower erosion tied to contract renewals and patient retention.

2) Does nevirapine still have use in HIV treatment guidelines today?

It can retain niche roles in specific patient contexts, but initiation rates tend to be lower than preferred regimen classes.

3) Are liquid nevirapine formulations more resilient than tablets economically?

They can be, because procurement and pediatric requirements can create separate tender dynamics and switch timing.

4) How do tenders and reimbursement rules influence VIRAMUNE net revenue?

They determine whether branded supply can remain preferred during contract windows; as generics win tenders, net revenue falls.

5) What competitive set most directly pressures VIRAMUNE pricing?

Generic nevirapine manufacturers in the same dosage forms and strengths, plus alternative NNRTIs and preferred regimen classes that reduce initiation demand.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. U.S. National Library of Medicine. (n.d.). Nevirapine information. DailyMed.
3. European Medicines Agency. (n.d.). Nevirapine product information. EMA.